Risk of seizure in patients with prostate cancer treated with enzalutamide in China: a noninterventional study
{{output}}
Background: Enzalutamide, approved in China for the treatment of prostate cancer (PC), has been studied for risk of seizure, but there is limited real-world evidence on this risk in China. Cases of posterior reversible encephalop... ...
